Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 5Recurrence 4Burkitt Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Follicular 3Leukemia 2Neoplasm, Residual 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 103fludarabine 61Methotrexate 49Dexamethasone 46fludarabine phosphate 45Cytarabine 45Vincristine 42blinatumomab 36Whole-Body Irradiation 33Mycophenolic Acid 30Tacrolimus 26Mercaptopurine 26Melphalan 26venetoclax 24Specimen Handling 24Etoposide 23Peripheral Blood Stem Cell Transplantation 21pegaspargase 20Stem Cell Transplantation 19Granulocyte Colony-Stimulating Factor 19Calcium Dobesilate 19Busulfan 19Doxorubicin 18Prednisone 17Rituximab 16Filgrastim 16Daunorubicin 16Asparaginase 16merphos 15Thiotepa 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × tisagenlecleucel × 1 year × Clear all
NCT04094311 2026-04-20

Study of Out of Specification for Tisagenlecleucel

Novartis

Phase 3 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06408194 2026-02-10

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Stanford University

Phase 1 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03642626 2026-01-23

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
150 enrolled 23 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡